Expand all sections

Secukinumab

Cosentyx

Extended indication Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in children and adole
Therapeutic value Possible equal value
Registration phase Registration application pending

Product

Active substance Secukinumab
Domain Chronic immune diseases
Reason of inclusion Indication extension
Main indication Skin diseases
Extended indication Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.
Proprietary name Cosentyx
Manufacturer Novartis
Mechanism of action Interleukin inhibitor
Route of administration Subcutaneous
Therapeutical formulation Injection
Budgetting framework Intermural (MSZ)
Additional remarks Monklonaal antilichaam gericht tegen IL-17A.

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Submission date November 2019
Expected Registration August 2020
Orphan drug No
Registration phase Registration application pending
Additional remarks Fabrikant verwacht registratie in Q3 2020

Therapeutic value

Current treatment options de volgende behandelingen zijn geregistreerd voor de behandeling van psoriasis, niet geselecteerd op leeftijd: adalimumab, golimumab, brodalumab, ixekizumab, secukinumab, infliximab, certolizumab pegol, etanercept, tofacitinib, baricitinib, ustekinumab, guselkumab, tildrakizumab, risankizumab, apremilast, abatacept.
Therapeutic value Possible equal value
Substantiation Er wordt verwacht dat secukinumab de concurrentie aan zal gaan met de andere anti-IL17 remmers.
References NCT03668613

Expected patient volume per year

Patient volume

< 100

Market share is generally not included unless otherwise stated.
References NHG-Standaard Psoriasis
Additional remarks Bij jonge kinderen is de prevalentie laag (ongeveer 0,4 per 1.000 patiënten per jaar). In Nederland zijn er 1,5 miljoen kinderen in de leeftijd van 6 tot 12 jaar. Dit betekent naar schatting 600 kinderen met deze indicatie. Naar verwachting gebruiken rond de 100 kinderen op dit moment biologicals deze groep komt mogelijk in aanmerking voor secukinumab.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.